Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | CSF3R |
| Variant | N579Y |
| Impact List | missense |
| Protein Effect | gain of function |
| Gene Variant Descriptions | CSF3R N579Y lies within fibronectin type-III domain 5 of the Csf3r protein (UniProt.org). N579Y confers a gain of function to Csf3r as demonstrated by cytokine-independent growth and increased Erk1/2 and Stat3 phosphorylation in cultured cells (PMID: 36579444). |
| Associated Drug Resistance | |
| Category Variants Paths |
CSF3R mutant CSF3R act mut CSF3R N579Y |
| Transcript | NM_000760.4 |
| gDNA | chr1:g.36467951T>A |
| cDNA | c.1735A>T |
| Protein | p.N579Y |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| XM_017000370.1 | chr1:g.36467951T>A | c.1735A>T | p.N579Y | RefSeq | GRCh38/hg38 |
| NM_172313.2 | chr1:g.36467951T>A | c.1735A>T | p.N579Y | RefSeq | GRCh38/hg38 |
| XM_011540748.3 | chr1:g.36467951T>A | c.1735A>T | p.N579Y | RefSeq | GRCh38/hg38 |
| XM_047446753.1 | chr1:g.36467951T>A | c.1735A>T | p.N579Y | RefSeq | GRCh38/hg38 |
| XM_005270493.1 | chr1:g.36467951T>A | c.1735A>T | p.N579Y | RefSeq | GRCh38/hg38 |
| NM_000760.3 | chr1:g.36467951T>A | c.1735A>T | p.N579Y | RefSeq | GRCh38/hg38 |
| XM_011540749.1 | chr1:g.36467951T>A | c.1735A>T | p.N579Y | RefSeq | GRCh38/hg38 |
| XM_011540749.1 | chr1:g.36467951T>A | c.1735A>T | p.N579Y | RefSeq | GRCh38/hg38 |
| NM_156039.3 | chr1:g.36467951T>A | c.1735A>T | p.N579Y | RefSeq | GRCh38/hg38 |
| NM_172313.3 | chr1:g.36467951T>A | c.1735A>T | p.N579Y | RefSeq | GRCh38/hg38 |
| NM_000760.4 | chr1:g.36467951T>A | c.1735A>T | p.N579Y | RefSeq | GRCh38/hg38 |
| XM_005270493.1 | chr1:g.36467951T>A | c.1735A>T | p.N579Y | RefSeq | GRCh38/hg38 |
| NM_156039.3 | chr1:g.36467951T>A | c.1735A>T | p.N579Y | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CSF3R N579Y | hematologic cancer | sensitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Jakafi (ruxolitinib) treatment inhibited colony formation and decreased viability of transformed cells expressing CSF3R N579Y in culture (PMID: 36579444). | 36579444 |